Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 296

1.

Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA.

Parida L, Haferlach C, Rhrissorrakrai K, Utro F, Levovitz C, Kern W, Nadarajah N, Twardziok S, Hutter S, Meggendorfer M, Walter W, Baer C, Haferlach T.

PLoS Comput Biol. 2019 Aug 30;15(8):e1007332. doi: 10.1371/journal.pcbi.1007332. eCollection 2019 Aug.

2.

Molecular characterization of acute myeloid leukemia patients who relapse more than 3 years after diagnosis: an exome sequencing study of 31 patients.

Hartmann L, Haferlach C, Meggendorfer M, Nadarajah N, Kern W, Haferlach T, Stengel A.

Haematologica. 2019 Aug 1. pii: haematol.2019.227702. doi: 10.3324/haematol.2019.227702. [Epub ahead of print]

3.

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.

Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C.

Blood. 2019 Oct 3;134(14):1132-1143. doi: 10.1182/blood.2019000402. Epub 2019 Jul 10. Review.

PMID:
31292114
4.

"Somatic" and "pathogenic" - is the classification strategy applicable in times of large-scale sequencing?

Baer C, Walter W, Hutter S, Twardziok S, Meggendorfer M, Kern W, Haferlach T, Haferlach C.

Haematologica. 2019 Aug;104(8):1515-1520. doi: 10.3324/haematol.2019.218917. Epub 2019 Jul 4. No abstract available.

5.

DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern.

Cappelli LV, Meggendorfer M, Dicker F, Jeromin S, Hutter S, Kern W, Haferlach T, Haferlach C, Höllein A.

Leukemia. 2019 Jun 17. doi: 10.1038/s41375-019-0502-0. [Epub ahead of print] No abstract available.

PMID:
31209279
6.

RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcome.

Stengel A, Kern W, Meggendorfer M, Haferlach T, Haferlach C.

Leuk Lymphoma. 2019 May;60(5):1334-1336. doi: 10.1080/10428194.2018.1522439. No abstract available.

PMID:
30997874
7.

Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.

Hartmann L, Haferlach C, Meggendorfer M, Kern W, Haferlach T, Stengel A.

Genes Chromosomes Cancer. 2019 Oct;58(10):698-704. doi: 10.1002/gcc.22761. Epub 2019 May 1.

PMID:
30994218
8.

Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes.

Ganster C, Müller-Thomas C, Haferlach C, Strupp C, Ogata K, Germing U, Hildebrandt B, Mallo M, Lübbert M, Müller C, Solé F, Götze KS, Vandenberghe P, Göhring G, Steinmetz T, Kröger N, Platzbecker U, Söling U, Raynaud S, Shirneshan K, Schanz J, Haase D.

Genes Chromosomes Cancer. 2019 Oct;58(10):689-697. doi: 10.1002/gcc.22760. Epub 2019 Apr 30.

PMID:
30994215
9.

Impact of 9q deletions on the classification of patients with acute myeloid leukemia.

Balk B, Haferlach T, Meggendorfer M, Kern W, Haferlach C, Stengel A.

J Cancer Res Clin Oncol. 2019 Mar 29. doi: 10.1007/s00432-019-02908-0. [Epub ahead of print] No abstract available.

PMID:
30927073
10.

Impact of assay procedures on detection of MR4.5 status in chronic myeloid leukemia: Optimization of cDNA synthesis.

Jeromin S, Eder C, Haferlach C, Haferlach T, Kern W.

Int J Lab Hematol. 2019 Oct;41(5):e109-e112. doi: 10.1111/ijlh.13004. Epub 2019 Mar 12. No abstract available.

PMID:
30860652
11.

Comprehensive molecular characterization of myeloid malignancies with 9q deletion.

Hartmann L, Haferlach T, Meggendorfer M, Kern W, Haferlach C, Stengel A.

Leuk Lymphoma. 2019 Mar 7:1-3. doi: 10.1080/10428194.2019.1585840. [Epub ahead of print] No abstract available.

PMID:
30844315
12.

European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms.

Rack KA, van den Berg E, Haferlach C, Beverloo HB, Costa D, Espinet B, Foot N, Jeffries S, Martin K, O'Connor S, Schoumans J, Talley P, Telford N, Stioui S, Zemanova Z, Hastings RJ.

Leukemia. 2019 Aug;33(8):1851-1867. doi: 10.1038/s41375-019-0378-z. Epub 2019 Jan 29. Review.

13.

Evidence of clonality in cases of hypereosinophilia of undetermined significance.

Pohlkamp C, Vetro C, Dicker F, Meggendorfer M, Kern W, Haferlach C, Haferlach T.

Leuk Lymphoma. 2019 Aug;60(8):2071-2074. doi: 10.1080/10428194.2018.1564825. Epub 2019 Jan 18. No abstract available.

PMID:
30656986
14.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

15.

Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma.

Stratmann JA, von Rose AB, Koschade S, Wendelin K, Köhler F, Heinsch M, Schiller K, Haferlach C, Wattad M, Rieder H, Serve H, Gökbuget N, Steffen B.

Ann Hematol. 2019 Mar;98(3):647-656. doi: 10.1007/s00277-018-03590-x. Epub 2019 Jan 6. Review.

PMID:
30613837
16.

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, Davis Z, Rigolin GM, Visentin A, Xochelli A, Delgado J, Baran-Marszak F, Stalika E, Abrisqueta P, Durechova K, Papaioannou G, Eclache V, Dimou M, Iliakis T, Collado R, Doubek M, Calasanz MJ, Ruiz-Xiville N, Moreno C, Jarosova M, Leeksma AC, Panayiotidis P, Podgornik H, Cymbalista F, Anagnostopoulos A, Trentin L, Stavroyianni N, Davi F, Ghia P, Kater AP, Cuneo A, Pospisilova S, Espinet B, Athanasiadou A, Oscier D, Haferlach C, Stamatopoulos K; ERIC, the European Research Initiative on CLL.

Blood. 2019 Mar 14;133(11):1205-1216. doi: 10.1182/blood-2018-09-873083. Epub 2019 Jan 2.

17.

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M.

Haematologica. 2019 May;104(5):955-962. doi: 10.3324/haematol.2018.206797. Epub 2018 Dec 4.

18.

Dreams can come true: the first steps toward a peripheral blood screening test for the early detection of tumors have been taken.

Haferlach C, Haferlach T.

Ann Oncol. 2019 Jan 1;30(1):12-13. doi: 10.1093/annonc/mdy499. No abstract available.

PMID:
30462156
19.

Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.

Stengel A, Kern W, Meggendorfer M, Haferlach T, Haferlach C.

Br J Haematol. 2019 Jun;185(5):951-954. doi: 10.1111/bjh.15653. Epub 2018 Nov 20. No abstract available.

PMID:
30460680
20.

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse.

Höllein A, Meggendorfer M, Dicker F, Jeromin S, Nadarajah N, Kern W, Haferlach C, Haferlach T.

Blood Adv. 2018 Nov 27;2(22):3118-3125. doi: 10.1182/bloodadvances.2018023432.

Supplemental Content

Loading ...
Support Center